Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed’s current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue”, or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in ResMed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.
Company Overview & Strategy
Who we are / what we do

• Listed on NYSE & ASX, ~$18B market cap

• World-leading connected health company with over 10 million 100% cloud-connectable devices
  – More than 11 million patients in AirView monitoring ecosystem
  – More than 90 million patient accounts in out-of-hospital care network

• Innovative designer and manufacturer of award-winning devices and cloud-based software solutions
  – Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions

• Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs

• Cloud-based software health applications and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers
  – Tools that allow fewer people to manage more patients
  – Empower patients to track own health outcomes
Why invest? – driving long-term shareholder value

Market Dynamics
- Underpenetrated markets in sleep and COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions

Growth & Innovation
- Global leader in connected health for sleep and respiratory care
- Long-term growth opportunities
- 5,800+ patents and designs
- ~7-8% of revenue invested in R&D

Financial Results
- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of disciplined capital deployment

Total Shareholder Return (NYSE shares as of 9/30/19):
- 1-yr 19%
- 3-yr 119%
- 5-yr 200%

1. Pending and issued patents and designs as of 9/30/2019
Key demographic, political, and healthcare trends present multiple opportunities for ResMed

Healthcare continues to rise in importance as a major topic on social and political agendas around the world.

Increasing Chronic Disease Burden
Aging Population
Healthcare Costs Growing
Physician Shortages

The shift to value-based healthcare and consumerization-of-care is here to stay.

Healthcare System Pain Points

Delivering the correct care when needed
Delivering care in lower cost settings
Patient Engagement
Documentation
Data Availability
Communication
Analytics

Integration of Data & Technology is key to driving increased awareness & treatment
ResMed 2025 Strategy: Patient-centric, digitally enabled strategy

250 million lives improved in out-of-hospital healthcare in 2025!

**Purpose**
- Empower people to live healthier and higher quality lives in the comfort of their home

**Growth Focus**
- Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings

**Growth Advantage**
- Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences and efficiency

**Growth Foundations**
- High-performing, diverse and entrepreneurial people
- Industry-leading innovation and business excellence
- Digital health technology and scientific leadership
Our Business - Sleep
Sleep business strategy

Deliver a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes

- **OPTIMIZE EFFICIENCIES FOR PROVIDERS**
  - Home medical equipment / home care provider-facing solutions that drive workflow efficiencies
  - Long-term adherence solutions that improve patient management and meet the needs of referring physicians

- **DELIVER BEST-IN-CLASS PATIENT EXPERIENCE**
  - Patient facing solutions, from identification to treatment, that streamline the experience and improve long-term adherence

- **EMBRACE AND ENABLE INTEGRATED CARE MODELS**
  - Payer-facing solutions that enable population management, backed by our data insights, outcomes research, and market access

Collaboration – Operating Excellence – Lean Innovation – High Performance Culture – Talent
What is sleep-disordered breathing?

- Abnormal respiration during sleep – the cessation of breathing or “sleep suffocation”
- Most prevalent is **obstructive sleep apnea** – collapse of the upper airway despite ongoing effort
- Other types include central sleep apnea -- lack of breathing and lack of effort -- and mixed apnea
The global prevalence of sleep apnea is enormous and growing...

Sleep apnea is more than 80% undiagnosed….

…and is highly prevalent in other chronic conditions

For every 100 U.S. adults...

4 KNOW THEY HAVE SLEEP APNEA

22 DON’T KNOW THEY HAVE IT

For every 100 U.S. adults...

- Sleep Apnea
- Atrial Fibrillation
- Heart Failure
- Drug-Resistant Hypertension
- Stroke
- Type 2 Diabetes
- Obesity

1 Peppard PE et al. Am J Epidemiol 2013
2 Young T et al. Sleep 1997
3 O’Keeffe T and Patterson EJ. Obes Surg 2004
4 Bitter T et al. Dtsch Arztebl Int. 2009
5 Oldenburg O et al. Eur J Heart Fail 2007
6 Logan AG et al. J Hypertens 2001
New research demonstrates dose response of PAP therapy

For every **one hour per night** increase in PAP usage there was an **8% decrease** in inpatient visits and a **4% decrease** in overall visits\(^1\).

---

\(^1\) Inpatient, ED, and observation visits

*Kirsch et al., Association of PAP use with acute care utilization and costs, JCSM 2019*
Transforming the treatment & management of sleep apnea

**Quiet**
- AirSense™ 10
- AirCurve™ 10

**Compact**
- AirMini™

**Comfortable**
- Minimalist
- Freedom
  - Sleep in any position.

**Connected**
- Ultra Soft
  - Patented memory foam offers unique comfort.
- Universal Fit
  - Classic designs that fit nearly every face.

- Brightree
- AirView™
- myAir™

© 2019 ResMed | Q1 2020 Investor Presentation | 14
Working with others to raise sleep as a public priority

Our sleep research joint venture with Verily

- Develop software solutions to help identify, diagnose, treat and manage those with OSA

- To study the health and financial impacts of untreated sleep apnea
  - Prove the ROI for treating OSA

With Verily, we can unlock richer, more holistic insights about sleep apnea and the value of treating it
Our Business– Respiratory Care
Respiratory care strategy

Changing the lives of COPD patients by bringing new solutions for unmet patient needs

**WIN IN THE CORE**
- Reach more COPD patients through connected non-invasive ventilation
- Drive profitable growth in life-support ventilation
- Grow POC sales through business model innovation

**INNOVATE AND EXPAND INTO ADJACENCIES**
- Treat patients earlier in COPD disease progression through a connected ecosystem
- Continue to leverage investments in life support and NIV
- Further innovate & scale the portable oxygen business model
- Better prove connected health value propositions

**TRANSFORM COPD HEALTHCARE DELIVERY**
- Build intelligent therapy solutions enabled by sensor technologies, data analytics, AI and ML with improved patient/care giver engagement
- Create value propositions in longitudinal care, predict exacerbations, and prevent hospitalization
- Support new business models & tailored products in emerging growth markets

Collaboration – Operating Excellence – Lean Innovation – High Performance Culture – Talent
What is chronic obstructive pulmonary disease (COPD)?

*COPD is a serious lung disease that over time, makes it hard to breathe*

**Causes include:**
- smoking, vaping, & second hand smoke
- pollution
- occupational exposure to noxious gases
- a history of childhood infections (could be a catalyst)
- genetic inheritance, leading to its onset
COPD is a large and growing market

- COPD is the third leading cause of death worldwide\(^1\)
- More than 380 million people worldwide are estimated to have COPD\(^2\)
  - Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil and E. Europe may be well over 100 million\(^3\)
- Cost to healthcare systems from COPD is enormous:
  - Europe: ~€48 billion per year\(^4\)
  - US: ~$50 billion per year\(^5\)
- More than 3 million people worldwide die each year due to COPD\(^6\)

---

\(^2\) https://www.ncbi.nlm.nih.gov/pubmed/26755942  
\(^3\) Company estimates based on World Health Organization estimates and Zhong et al. “Prevalence of Chronic Obstructive Pulmonary Disease in China” Respiratory and Critical Care  
There is a need for end-to-end solutions for COPD patients

Global population of COPD patients: ~380 million

- Self-management (Smoking Cessation, Diet, Exercise)
- Inhaled Pharmaceuticals for COPD
- Oxygen
- Ventilation

Full spectrum of solutions for respiratory care
Study Overview:
Cleveland Clinic enrolled people into Propeller as part of their routine clinical care and monitored them for at least one year. Providers monitored drug use and adherence to inhaled controller medications, providing follow-up as needed.

Population:
- COPD patients with ≥1 utilization (Emergency Department (“ED”) visit or hospitalization) in prior 12 months
- N = 39; mean age: 69 years, 51% male, 69% African American, mean FEV1\(^1\) predicted: 47.2%, mean CAT: 19\(^2\)

Results:

<table>
<thead>
<tr>
<th>Healthcare Utilization</th>
<th>12 months prior</th>
<th>12 months during monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause</td>
<td>4.7 ± 4.1</td>
<td>3.4 ± 2.6</td>
</tr>
<tr>
<td>COPD</td>
<td>3.4 ± 3.2</td>
<td>2.2 ± 2.3</td>
</tr>
</tbody>
</table>

\(^1\) FEV1 = Forced Expiratory Volume in 1 second – the volume of air that can be forcibly blown out in the first second after full inspiration. Values between 80% and 120% are considered normal

\(^2\) CAT = COPD Assessment Test – an eight-item questionnaire designed to quantify the impact of COPD symptoms on a patient’s health status. Scored between 0-40, <10 Low, 10-20 Medium, 21-30 High, >30 Very high

Our Business – Software as a Service (SaaS)

- Single view of the patient
- Comprehensive interoperability
- Care transition, coordination and collaboration
- Seamless access to information for patients and those who care for them
- Manage populations across provider / care settings
- Data insights to enable better care / better results

Connected systems deliver the best outcomes for value-based care
Our SaaS portfolio…
…supports a broad portfolio of out-of-hospital verticals

MatrixCare

- Home Health
- Hospice
- Private Duty
- Skilled Nursing
- Senior Living
- Life Plan Community

Brightree

- HME Providers

ResMed

- Sleep and RC Products & Solutions
Strong positioning within key segments

- Brightree – #1 in HME market with opportunity to grow
- Moving upmarket in Home Health and Hospice (HHP) with Brightree and HEALTHCAREfirst combined offering managed by MatrixCare
  - HHP platform recently named the preferred solutions partner by Cerner, a leading provider of hospital systems
- MatrixCare awarded third straight Best in KLAS Award for Long-Term Care Software

<table>
<thead>
<tr>
<th></th>
<th>HME</th>
<th>Home Health &amp; Hospice</th>
<th>Skilled Nursing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated No. of Providers</td>
<td>6,000</td>
<td>16,000</td>
<td>16,000</td>
</tr>
<tr>
<td>Estimated HCIT Market Size</td>
<td></td>
<td></td>
<td>$1.5B</td>
</tr>
</tbody>
</table>

Increased competitive advantage as market moves to value based care models and providers look to integrate across care settings
SaaS portfolio is operating at scale and creating value

Portfolio is financially attractive on its own and with leading positions in key segments.

Supports growth for existing businesses (HME) and chronic diseases, sleep apnea and COPD in particular.

Breadth and scale creates our competitive advantage.
Digital Health Technology
Purpose: Enable all ResMed businesses to achieve their business objectives by leveraging Healthcare Informatics technology and Advanced Analytics.

Digital health technology supports all of ResMed

Digital Health Technology

Sleep  Respiratory Care  SaaS

Technology + Advanced Analytics
Digital health technology strategy

**Connected Health Ecosystem**
- Innovate for core Sleep and RC business
  - Device connectivity to the cloud
  - Patient monitoring and management
  - Patient engagement

**Out-of-Hospital SaaS Ecosystem**
- ePrescribe and Resupply
- Integrations with our SaaS platforms
- Accelerating the ResMed value proposition for our customers and patients

**Data Analytics – The AI/ML Journey**
- Drive better clinical outcomes for patients and business outcomes for providers
- Leverage big data to derive meaningful actionable insights, more than 5 billion nights of sleep data
- Talented team of data scientists using artificial intelligence and machine learning to improve long-term patient adherence
We transform 5+ billion nights of medical data into useful outcomes

End-to-end connected health solutions in sleep, respiratory care, and out-of-hospital healthcare
| **AirView™** has over 11 million patients | **10+ million**
| 1 million+ diagnostic tests processed **in the cloud** | 100% cloud connectable devices worldwide |
| ~100 API calls **per second** from integrators | ~93 million accounts in out-of-hospital care network |
|  | 2 million+ patients have signed up for **myAir™** |
Recent financial results
Q1 FY20 financial results

<table>
<thead>
<tr>
<th></th>
<th>1Q20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$681.1M</td>
</tr>
<tr>
<td></td>
<td>+16% (+17% CC)</td>
</tr>
<tr>
<td>Gross margin</td>
<td>59.5%</td>
</tr>
<tr>
<td></td>
<td>+120 bps</td>
</tr>
<tr>
<td>Non-GAAP operating income*</td>
<td>$191.0M</td>
</tr>
<tr>
<td></td>
<td>+22%</td>
</tr>
<tr>
<td>Non-GAAP EPS*</td>
<td>$0.93</td>
</tr>
<tr>
<td></td>
<td>15%</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$139.7M</td>
</tr>
</tbody>
</table>

* ResMed adjusts for the impact of the amortization of acquired intangibles and deferred revenue fair value adjustment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
Track record of disciplined financial growth

Revenue ($B)

- LTM 1Q15: $1.6
- LTM 1Q20: $2.7

11% CAGR

Non-GAAP Operating Income ($M)

- LTM 1Q15: $411
- LTM 1Q20: $750

13% CAGR

Non-GAAP EPS

- LTM 1Q15: $2.47
- LTM 1Q20: $3.77

9% CAGR

Fiscal Years ended June 30
Recognized by Forbes as #1 in our category for corporate citizenship

<table>
<thead>
<tr>
<th>Eliminating unnecessary waste</th>
<th>Minimizing pollution</th>
<th>Product stewardship</th>
<th>Responsible compliance</th>
<th>Increased awareness and continual improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>We work to eliminate unnecessary waste in all our systems &amp; processes, such as minimizing our use of natural resources.</td>
<td>We are minimizing pollution, in particular our non-biodegradable waste to landfill.</td>
<td>We design and develop products with reduced impact on the environment through their lifecycle.</td>
<td>We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in.</td>
<td>We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements</td>
</tr>
</tbody>
</table>

Recognized by others for leading in this space:

1. #18 on Forbes & Just Capital’s “2019 Just 100”, #1 in Healthcare Equipment and Services
2. #170 on WSJ’s 2018 Management Top 250 of the U.S.’s most well-run companies for customers, employees, and investors
In the last 12 months, we changed approximately **15 million lives** with our products and improved **93 million more** via our out-of-hospital care network.

Our aspiration is to improve **250 million lives** in 2025.
ResMed is the global leader in connected health

**Market Dynamics**
- Underpenetrated markets in sleep and COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions

**Growth & Innovation**
- Global leader in connected health for sleep and respiratory care
- Long-term growth opportunities
- 5,800+ patents and designs\(^1\)
- ~7-8% of revenue invested in R&D

**Financial Results**
- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of disciplined capital deployment

**Total Shareholder Return (NYSE shares as of 9/30/19):**
- 1-yr 19%
- 3-yr 119%
- 5-yr 200%

---
1. Pending and issued patents and designs as of 9/30/2019

Thank you

Contact Investor Relations
Phone: (858) 836-5971
Email: investorrelations@resmed.com
Website: investor.resmed.com
APPENDIX
Turning big data into actionable information

Pioneering innovation and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers

AirView™

- 21% patient adherence with automated compliance coaching¹
- 59% reduction in labor costs²
- 55% increase in new patient setups³

myAir™

- World's largest study for adherence
  - > 128,000 patients

Patient adherence with patient engagement⁴

1. Hwang, et al., AJRCCM 2017
3. Data based on monthly patient setups and compliance rates of DME customers from February 2014 – March 2015. Historical results for this provider over the stated time.
ResAdhere: remote monitoring + mask resupply drive improved adherence

In a study of ~100k patients with AirView cloud-connected devices…

…the likelihood of therapy termination decreased by >50% after one-year

and there was a significant increase in daily PAP usage

Benjafield, et al. AJRCCM 2018 (abstract)
Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings.
Big data analysis drives insights for treatment of central sleep apnea

Patients with treatment-emergent central sleep apnea (CSA) are two times more likely to terminate therapy

- Opportunity to rethink conventional therapeutic options
- Minimize risk of therapy termination through early diagnosis
- Regularly monitor patients to support adherence to treatment

Analysis of ~200k CSA patients

- Switching from therapy CPAP to ASV improved relative adherence by 22%
- Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep
Reducing mortality with PAP therapy

U.S. multicenter, population-based cohort study

• Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality

• Death rate was twice as high for persons who did not receive positive airway pressure therapy
  – (24.7 vs 12.8 deaths per 1000 person years, \( p = 0.03 \))

Lisan et al., Association of PAP prescription with mortality in patients with obesity and severe OSA. The Sleep Heart Health Study, JAMA Otolaryngol Head Neck Surg 2019
Opportunity to shift care from hospital to home

- Healthcare costs are on the rise
- Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT)
  - Reduces hospitalization and mortality by 51%
  - Increases time to hospital readmission or death by ~90 days

1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451.

- Combination of HOT with NIV reduced hospital readmissions by 58.3%
- Combination of therapies provided improved patient quality of life and saved >$50k per quality of life adjusted year
Respiratory Care: Our point of view

- People with COPD are not well served by healthcare systems today
  - Better solutions are needed for patients, physicians, care providers, and payers

- Technology enabled medical devices will be incorporated within integrated care models to more effectively manage patient needs

- Improving outcomes in Respiratory Care will require solutions that reach the patient much earlier in their disease progression

- Digitally enabled, end-to-end solutions will be the key to reaching and supporting the millions of patients with chronic respiratory diseases in emerging markets
Digital health solutions for inhaled COPD pharmaceuticals

**Acquired Propeller Health in January 2019**

- ResMed now has end-to-end solutions for Digital Health for COPD patients across stages I, II, III, IV of the disease
- Uses sensors with inhalers to track medication usage and provide personal feedback and insights
- Establishes ResMed as a leading provider of COPD and asthma patient management solutions
- Enables digitally-enabled integration of care through the progression of the disease

**UPSTREAM**

Customers include:

- gsk
- Boehringer Ingelheim
- ORION
- NOVARTIS

Pharma companies signed represent 90% of long-acting respiratory inhalation drugs

**DOWNSTREAM**

- Payers: **Anthem**
- PBMs: **Express Scripts**
- Health systems: **Dignity Health**
- Pharmacies: **Walgreens**

**Propeller**

- Increased drug adherence and sales
- Improved clinical trial speed and enhanced time to market
- Clinical insights and efficiencies
- Health and economic outcomes
- Patient Acquisition

Patients + $$

© 2019 ResMed | Q1 2020 Investor Presentation | 48
Propeller has demonstrated compelling clinical outcomes

**Impact of the Propeller solution tracking inhaler usage and location**

**Uncontrolled COPD**
- **SABA use over time**
  - # per day
  - Drives a decrease in medication
- **Symptom free days**
  - %
  - Drives an improvement in QOL
  - +32%
- **Healthcare utilization**
  - Events
  - Drives a reduction in healthcare utilization
  - Before: 79, After: 59 (-25%)

**Uncontrolled Asthma**
- **Adherence**
  - %
  - Drives an improvement in adherence
  - Control: 36, Intervention: 57 (+58%)
- **QoL: Rescue Inhaler use per day**
  - # times used
  - Drives an improvement in QOL
  - Pre-enrollment: 13, Post-enrollment: 6 (-54%) and 12 (-17%) and 2 (-67%)
- **Acute care utilization**
  - Events per 100 patient years
  - Drives a reduction in healthcare utilization
  - ED + Hosp.: 13, ED: 6, Hosp.: 2 (100%)
### History of successful SaaS acquisitions

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
<th>Date</th>
<th>Key Product</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UMBikan</strong></td>
<td>Halifax, NS Canada</td>
<td>Aug 2012</td>
<td>U-Sleep</td>
<td>Integrated into AirView.</td>
</tr>
<tr>
<td><strong>GoJaysec</strong></td>
<td>Knoxville, TN</td>
<td>Feb 2015</td>
<td>GoJaysec</td>
<td>Rebranded as GoScripts.</td>
</tr>
<tr>
<td><strong>CareTouch</strong></td>
<td>Denver, CO</td>
<td>Jul 2015</td>
<td>CareTouch 360</td>
<td>Rebranded as ResMed ReSupply.</td>
</tr>
<tr>
<td><strong>Brightree</strong></td>
<td>Lawrenceville, GA</td>
<td>Feb 2016</td>
<td>Brightree Core</td>
<td>Operating as a wholly-owned subsidiary.</td>
</tr>
<tr>
<td><strong>Conduittech</strong></td>
<td>Girard, PA</td>
<td>Jun 2017</td>
<td>MyForms</td>
<td>Integrated into Brightree.</td>
</tr>
<tr>
<td><strong>AllCall Connect</strong></td>
<td>Joliet, IL</td>
<td>Jul 2017</td>
<td>Brightree ConnectPRO</td>
<td>Integrated into Brightree.</td>
</tr>
<tr>
<td><strong>Healthcare First</strong></td>
<td>Springfield, MO</td>
<td>Jul 2018</td>
<td>firstHOMECARE Software (EHR)</td>
<td>Integrated with Brightree and MatrixCare.</td>
</tr>
<tr>
<td><strong>MatrixCare</strong></td>
<td>Bloomington, MN</td>
<td>Nov 2018</td>
<td>MatrixCare One</td>
<td>Operating as a wholly owned subsidiary.</td>
</tr>
<tr>
<td><strong>Apacheta</strong></td>
<td>Media, PA</td>
<td>Dec 2018</td>
<td>Apacheta ACE (a mobile enterprise application platform)</td>
<td>Operating as a part of Brightree, with an independent brand.</td>
</tr>
</tbody>
</table>